Cardiogenetic testing

Cardiogenetic testing: when CVD risk is hereditary

In many patients, the risk of cardiovascular disease (CVD) may be attributed to genetic polymorphisms and mutations.1 Quest Diagnostics offers cardiogenetic testing to aid in early diagnosis and earlier treatment for affected patients, as well as family members.

Familial hypercholesterolemia

Familial hypercholesterolemia (FH) refers to a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease (CHD). These defects are found in the FH genes, LDL receptor (LDLR), apolipoprotein B (ApoB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and possibly others.

Today, FH is generally underdiagnosed and undertreated. With the help of genetic testing, you can change that trend. Cardio IQ® genetic testing for FH from Quest detects mutations on the LDLR, ApoB, and PCSK9 genes to enable an early, specific diagnosis of FH.
Get the full FH story.

Other Cardio IQ® cardiogenetic markers

Cardio IQ® cardiogenetic testing helps provide deeper insight into genetic risk of CVD as well as therapy selection.

Cardio IQ® cardiogenetic testing from Quest

Test name Clinical utility
Cardio IQ® 4q25 AF
Risk Genotype
Aids in the assessment of risk of atrial fibrillation and cardioembolic stroke
Cardio IQ® 9p21 Genotype Aids in the assessment of risk associated with myocardial infarction (MI), especially before age 50 in males and age 60 in females
Cardio IQ® Apolipoprotein
E (ApoE) Genotype
Helps determine the subtypes of ApoE which will aid in the risk assessment of coronary heart disease (CHD) and hyperlipoproteinemia
Cardio IQ® CYP2C19
Genotype
Helps assess likelihood of reduced or enhanced clopidogrel response. Guides treatment strategy for patients being considered for, or receiving, antiplatelet therapy
Cardio IQ® KIF6 Genotype Helps detect a gene variant associated with CHD risk and such CHD events as may be reduced from statin therapy
Cardio IQ® LPA
Aspirin Genotype
Helps identify individuals who are at risk of having elevated plasma lipoprotein (a) [Lp (a)] and increased cardiovascular risk which could be reduced by low-dose aspirin therapy
Cardio IQ® LPA
Intron-25 Genotype
Helps identify individuals at risk for elevated plasma lipoprotein (a) [Lp (a)] and increased cardiovascular risk

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.

 

Assess risk and guide therapy with cardiogenetic testing

Download an FH clinical history form

Download a cardiology genetics requisition form

Download the FH testing and services overview brochure

Download the FH genetic screening patient brochure

Contact Quest Genomics Client Services to speak with a
genetic counselor at 1.866.436.3463

 

References

  1. Centers for Disease Control and Prevention. Family history and other characteristics that increase risk for heart disease. Available at https://www.cdc.gov/heartdisease/family_history.htm. Accessed September 4, 2018.